ArticleThe Journal of antimicrobial chemotherapy2018
Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.
Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 94 citations in OpenAlex.
- Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- Profiling the host defense responses againstmLife · 2026Article
- The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis.Infection and drug resistance · 2026Review
- Xenosiderophore transporter gene expression and clade-specific filamentation in Candida auris killifish (Aphanius dispar) infection.Communications biology · 2025Article
- Evaluation of the Ca37 Monoclonal Antibody Targeting Alcohol Dehydrogenase AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Rezafungin: A Review in Invasive Candidiasis.Drugs · 2025Review
- New Perspectives on Antimicrobial Agents: Rezafungin.Antimicrobial agents and chemotherapy · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Recent increase inAntimicrobial agents and chemotherapy · 2024Article
- In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against FourJournal of fungi (Basel, Switzerland) · 2024Article
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- A Mini-Review of In Vitro Data forJournal of fungi (Basel, Switzerland) · 2024Review
- Efficacy of the combination of amphotericin B and echinocandins againstMicrobiology spectrum · 2024Article
- The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.Mycopathologia · 2023Review
- Rezafungin: First Approval.Drugs · 2023Review
- Challenges in the diagnosis and treatment of candidemia due to multidrug-resistantFrontiers in fungal biology · 2023Article
- Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.Infection and drug resistance · 2023Review
- Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Background: Multiple cases of Candida auris infection have been reported with high mortality rates owing to its MDR nature. Rezafungin (previously CD101) is a novel echinocandin with enhanced stability and pharmacokinetics that achieves high plasma drug exposure and allows for once weekly dose administration. Objectives: Evaluate the efficacy of rezafungin in the treatment of disseminated C. auris infection using a mouse model of disseminated candidiasis. Methods: Mice were immunosuppressed 3 days prior to infection and 1 day post-infection. On the day of infection, mice were inoculated with 3 × 107C. auris blastospores via the tail vein. Mice were randomized into four groups (n = 20): rezafungin at 20 mg/kg, amphotericin B at 0.3 mg/kg, micafungin at 5 mg/kg and a vehicle control. Treatments were administered 2 h post-infection. Rezafungin was given additionally on days 3 and 6 for a total of three doses, while the remaining groups were treated every day for a total of seven doses. Five mice from each group were sacrificed on days 1, 4, 7 and 10 of the study. Kidneys were removed from each mouse to determine the number of cfu for each respective day. Results: Rezafungin had significantly lower average log10 cfu/g of tissue compared with amphotericin B- and vehicle-treated mice on all days when kidneys were harvested. Additionally, rezafungin-treated mice had significantly lower average log10 cfu/g of tissue compared with micafungin-treated mice on day 10. Conclusions: Our findings show that rezafungin possesses potent antifungal activity against C. auris in a disseminated model of candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.